depression glp-1 GLP-1s: Are We Ignoring the Psychiatric Risks? Skinny but Suicidal: GLP-1 Receptor

In February 2026, the FDA publicly announced its intent to take action targeting mass-marketed, non-FDA-approved compounded GLP1 products, emphasizing that promotional claims implying equivalence to FDAapproved drugs can trigger enforcement risk

The initial four agents selected by RECOVER-TLC continue to advance toward Long COVID clinical trials

by Emily J

With the exception of Harvoni, Mounjaro and Zepbound are the only launch products ever to surpass $5 billion in sales in their first 12 months and their sales have only continued to grow

Although a recent meta-analysis showed an increased risk of GRC and aborted EGDs with GLP-1 RA use, it could not definitively establish a link to aspiration events due to limited data

Learn symptoms, when to seek care